Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Comment by MrMonkon Oct 02, 2013 9:15pm
137 Views
Post# 21786452

RE:Termination agreement by JV....................

RE:Termination agreement by JV....................It may go to 5 cents or it may go to 15 or cents - nobody knows which way the wind blows.

The resource payment for Hecla/Aurizon was simply too rich based on prevailing mining industry conditions.  It's not surprising that they walked.  True that Niogold preferred to have a partner to finance this thing right to production - sometimes better to have a smaller piece of a big pie than a large piece of a smaller pie.  However, they're in a good spot now - a nice resource with some cash in the bank - and it's not like they don't have any options.  I suspect that someone will recognize the value of the deposit - another JV partner who needs to add ounces.  Don't be surprised if another JV partner is accounced in the coming months.  Until then, we must sit back and watch the stock do what it will (or sell if you're done with this stock or the sector in general).

-- MM
<< Previous
Bullboard Posts
Next >>